Home | miyaokalab

Genome Editing in Human iPS Cells to Study and Cure Disease

Human iPS (induced pluripotent stem) cells have the potential to allow us to study diseases in virtually any type of human cell, and develop cell transplantation-based therapies. Our team is developing and improving genome editing technology in iPS cells. We are developing novel isogenic iPS cell-based disease models, and correcting mutations in iPS cells from patients, a critical step in transplantation-based therapies. Our current focus is on diseases affecting cardiomyocytes and hepatocytes. →More

English

日本語

News

2021. 4. 1.　Anri Saitoh (officially) and Minato Maeda start their BS theses in the lab.

2021. 2. 27.　Dr. Miyaoka together with Dr. Md. Shamsuzzoha Bayzid and Dr. Clara Li are awarded Interstellar Initiative (AMED, NYAS) Outstanding Presentation Award

2021. 2. 26.　Book about genome editing applications is published. Miyaoka and Kato wrote about off-target detection/analysis and mosaicism, respectively.

2021. 1. 12.　Minato Maeda joins the lab as an intern.

2020. 12. 9.　Hitomi Yako joins the lab as an intern.

2020. 10. 30.　We take lab photos while keeping social distance

2020. 10. 26.　We hire a lab tech.

2020. 10. 14.　Introductory book about genome editing is highlighted in "Newswitch" website. Congrats to Dr. Charpentier and Dr. Doudna!

2020. 10. 1.　Anri Saitoh starts her BS thesis in the lab.